European Economic AreaNorthern IrelandBiocidal Products Regulation (BPR)

IPBC Alternatives Face Challenges In Meeting EU Biocidal Regulations

The search for alternatives to IPBC under EU BPR highlights significant limitations in efficacy, availability, and application scope. Fludioxonil and Pythium oligandrum, the shortlisted substitutes, fail to meet the broad requirements of construction material preservation. Maintaining IPBC remains crucial while long-term solutions are explored.

Published in December 2024. Dates, deadlines and stages may have changed since.

Dr Steven Brennan

2 min readAI-drafted, expert reviewed

Construction materials

The EU evaluation of alternatives to 3-iodo-2-propynylbutylcarbamate (IPBC), a fungicidal biocide widely used for preserving construction materials, has revealed significant technical and regulatory obstacles. While alternatives such as Fludioxonil and Pythium oligandrum were assessed, neither meets the broad efficacy and usability of IPBC under current Biocidal Products Regulation (BPR) requirements.

IPBC’s Role And Regulatory Challenges

IPBC is a crucial component in construction material preservatives under Product Type (PT) 10, protecting non-wood materials from fungal damage. However, its potential classification as an environmental endocrine disruptor under BPR’s substitution criteria has prompted an in-depth analysis of alternatives​​.

Evaluated Alternatives

The analysis identified two main candidates:

Fludioxonil: A chemical fungicide with limited application to indoor use. Despite its technical feasibility in some scenarios, it lacks authorization for outdoor uses and availability in approved biocidal products​.Pythium oligandrum: A biological alternative suitable for indoor applications using waterborne formulations. However, its limited spectrum of efficacy and inability to serve in solvent-based or outdoor formulations restrict its viability​.

Challenges With Alternatives

Both alternatives fall short in addressing the comprehensive demands of construction material preservation, including efficacy, formulation compatibility, and market availability. Fludioxonil’s classification as a potential per- and polyfluoroalkyl substance (PFAS) also raises concerns over future regulatory restrictions​​.

Economic And Technical Constraints

Developing new biocidal substances faces prohibitive costs, averaging €10 million over a 10-year timeline. This deters innovation, leaving the industry dependent on existing substances that meet stringent BPR criteria​.

The absence of viable alternatives underscores IPBC’s critical role in PT 10 applications. The report advocates maintaining IPBC’s availability while exploring long-term innovations to meet environmental and safety standards​​.

Questions about this change

Why is IPBC being reviewed under EU regulations?

IPBC is under scrutiny as a potential environmental endocrine disruptor, necessitating an analysis of alternatives to comply with Biocidal Products Regulation (BPR) criteria.

What are the main barriers to replacing IPBC?

Alternatives like Fludioxonil and Pythium oligandrum face challenges in availability, technical compatibility, and comprehensive efficacy, making them unsuitable for widespread application.

Dr Steven Brennan

CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.

More from Dr Steven Brennan

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX